Neuronetics, Inc. (NASDAQ:STIM – Get Free Report) was the recipient of a significant decrease in short interest in April. As of April 15th, there was short interest totalling 57,700 shares, a decrease of 39.0% from the March 31st total of 94,600 shares. Based on an average trading volume of 170,500 shares, the days-to-cover ratio is presently 0.3 days.
Neuronetics Stock Performance
Shares of NASDAQ:STIM traded down $0.03 during midday trading on Friday, reaching $3.49. 44,573 shares of the company’s stock traded hands, compared to its average volume of 120,448. Neuronetics has a 1 year low of $1.03 and a 1 year high of $5.07. The company has a current ratio of 4.73, a quick ratio of 4.33 and a debt-to-equity ratio of 1.73. The company has a fifty day simple moving average of $3.92 and a two-hundred day simple moving average of $2.80.
Neuronetics (NASDAQ:STIM – Get Free Report) last announced its earnings results on Tuesday, March 5th. The company reported ($0.19) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.07. Neuronetics had a negative return on equity of 72.76% and a negative net margin of 42.31%. The firm had revenue of $20.31 million for the quarter, compared to analyst estimates of $19.73 million. During the same quarter last year, the firm posted ($0.30) EPS. As a group, research analysts forecast that Neuronetics will post -0.92 EPS for the current year.
Insider Activity
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently made changes to their positions in the business. G2 Investment Partners Management LLC purchased a new position in shares of Neuronetics during the 4th quarter valued at approximately $213,000. Millrace Asset Group Inc. lifted its holdings in Neuronetics by 205.1% in the 4th quarter. Millrace Asset Group Inc. now owns 725,369 shares of the company’s stock valued at $2,104,000 after purchasing an additional 487,591 shares in the last quarter. Worth Venture Partners LLC purchased a new position in Neuronetics in the 4th quarter valued at $30,000. Thompson Siegel & Walmsley LLC purchased a new position in Neuronetics in the 4th quarter valued at $545,000. Finally, Fielder Capital Group LLC purchased a new position in Neuronetics in the 4th quarter valued at $66,000. Hedge funds and other institutional investors own 53.59% of the company’s stock.
Wall Street Analysts Forecast Growth
Several equities research analysts have commented on STIM shares. Piper Sandler restated an “overweight” rating and issued a $8.00 price objective (up previously from $7.00) on shares of Neuronetics in a research report on Wednesday, March 6th. William Blair restated a “market perform” rating on shares of Neuronetics in a research report on Tuesday, March 26th.
Get Our Latest Research Report on STIM
About Neuronetics
Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.
Further Reading
- Five stocks we like better than Neuronetics
- Investing in the High PE Growth Stocks
- MarketBeat Week in Review – 4/22 – 4/26
- How to Invest in the FAANG Stocks
- 3 Stocks Leading the U.S. Agriculture Comeback
- Financial Services Stocks Investing
- How to Use Put Debit Spreads to Profit From Falling Stocks
Receive News & Ratings for Neuronetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuronetics and related companies with MarketBeat.com's FREE daily email newsletter.